Simple jQuery Dropdowns

Browsing by Author Caicun Zhou

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 3 of 3
Issue DateTitleAuthor(s)
1-May-2019Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 studyCaicun Zhou; Sang We Kim; Thanyanan Reungwetwattana; Jianying Zhou; Yiping Zhang; Jianxing He; Jin Ji Yang; Ying Cheng; Se Hoon Lee; Lilian Bu; Tingting Xu; Li Yang; Chao Wang; Ting Liu; Peter N. Morcos; You Lu; Li Zhang; Sun Yat-Sen University Cancer Center; Tongji University; Zhejiang Cancer Hospital; West China School of Medicine/West China Hospital of Sichuan University; Guangdong General Hospital; Asan Medical Center; SungKyunKwan University, School of Medicine; Faculty of Medicine, Ramathibodi Hospital, Mahidol University; Guangzhou Medical University; F. Hoffmann-La Roche AG; Zhejiang University; Roche Innovation Center; Jilin Cancer Hospital; Roche Pharma Development
20-Nov-2018CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancerThanyanan Reungwetwattana; Kazuhiko Nakagawa; Byoung Chul Cho; Manuel Cobo; Eun Kyung Cho; Alessandro Bertolini; Sabine Bohnet; Caicun Zhou; Ki Hyeong Lee; Naoyuki Nogami; Isamu Okamoto; Natasha Leighl; Rachel Hodge; Astrid McKeown; Andrew P. Brown; Yuri Rukazenkov; Suresh S. Ramalingam; Johan Vansteenkiste; Yonsei Cancer Center; Chungbuk National University Hospital; Gachon University; Tongji University; KU Leuven– University Hospital Leuven; Faculty of Medicine, Ramathibodi Hospital, Mahidol University; Universitätsklinikum Schleswig-Holstein Campus Lübeck; National Hospital Organization, Japan; Hospital Regional Universitario Carlos Haya; Kyushu University; Ontario Cancer Institute University of Toronto; AstraZeneca; Emory University School of Medicine; Kindai University; Hospital of Sondrio
2-Jan-2020Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLCSuresh S. Ramalingam; Johan Vansteenkiste; David Planchard; Byoung Chul Cho; Jhanelle E. Gray; Yuichiro Ohe; Caicun Zhou; Thanyanan Reungwetwattana; Ying Cheng; Busyamas Chewaskulyong; Riyaz Shah; Manuel Cobo; Ki Hyeong Lee; Parneet Cheema; Marcello Tiseo; Thomas John; Meng Chih Lin; Fumio Imamura; Takayasu Kurata; Alexander Todd; Rachel Hodge; Matilde Saggese; Yuri Rukazenkov; Jean Charles Soria; Yonsei Cancer Center; Jilin Provincial Cancer Hospital; Shanghai Pulmonary Hospital; Chang Gung University College of Medicine; KU Leuven– University Hospital Leuven; Institut de Cancerologie Gustave Roussy; Kansai Medical University; Université Paris-Sud; National Cancer Center Hospital; University of Toronto; Faculty of Medicine, Ramathibodi Hospital, Mahidol University; Hospital Regional Universitario Carlos Haya; Università degli Studi di Parma, Facoltà di Medicina e Chirurgia; Chungbuk National University, College of Medicine; Austin Health; Moffitt Cancer Center; Maidstone Hospital; AstraZeneca; Emory University School of Medicine; Chiang Mai University; Osaka International Cancer Institute